Aurobindo’s Unit 1 is undergoing a USFDA audit, as per media reports. Unit 1 is an API unit with manufacturing capabilities in CVS, CNS, Anti-allergics, and non-sterile Cephalosporins. The audit has started on April 16 and will last until 20 April 2018. The audit is being carried out by USFDA inspector Ms Nicole E Knowlton.

Investors/traders should watch the scrip as there is a rise in the USFDA Form 483 observations in the recent audits of Dr. Reddy, Sun Pharma, Cipla, Alkem, Indoco Remedies and Aurobindo’s Unit IV (injectable unit). – India Info Line

10 Diagnostic Imaging Trends for 2018



Digital version